Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
- SEC Filing
Camp4 Therapeutics (NASDAQ:CAMP) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(...
Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Overweight rating an...
JP Morgan analyst Anupam Rama downgrades Camp4 Therapeutics (NASDAQ:CAMP) from Overweight to Neutral.
Piper Sandler analyst Edward Tenthoff maintains Camp4 Therapeutics (NASDAQ:CAMP) with a Overweight and lowers the price targ...
